Combined blood markers correctly detect early pancreatic cancer in human cancer cells
A newly identified biomarker panel could pave the way to earlier detection and better treatment for pancreatic cancer, according to new research from the Perelman School of Medicine at University of Pennsylvania. Currently over 53,000 people in the United States are diagnosed with pancreatic cancer — the fourth leading cause of cancer death — every year. The blood biomarkers, detailed today in Science Translational Medicine, correctly detected pancreatic cancer in blood samples from patients at different stages of their disease.
The majority of pancreatic cancer patients are not diagnosed until an advanced stage, beyond the point at which their tumors can be surgically removed.
A team led by Ken Zaret, PhD, director of the Penn Institute for Regenerative Medicine and the Joseph Leidy Professor of Cell and Developmental Biology, and Gloria Petersen, PhD, from the Mayo Clinic, identified a pair of biomarkers that physicians could soon use to discover the disease earlier.
“Starting with our cell model that mimics human pancreatic cancer progression, we identified released proteins, then tested and validated a subset of these proteins as potential plasma biomarkers of this cancer,” Zaret said. The authors anticipate that health care providers will use the early-detection biomarkers to test for their presence and levels in blood from pancreatic cancer patients and blood drawn from individuals with a high risk of developing pancreatic cancer, including those who have a first-degree relative with pancreatic cancer, are genetically predisposed to the disease, or who had a sudden onset of diabetes after the age of 50.
“Early detection of cancer has had a critical influence on lessening the impact of many types of cancer, including breast, colon, and cervical cancer. A long standing concern has been that patients with pancreatic cancer are often not diagnosed until it is too late for the best chance at effective treatment,” said Robert Vonderheide, MD, DPhil, director of the Abramson Cancer Center (ACC) at the University of Pennsylvania. “Having a biomarker test for this disease could dramatically alter the outlook for these patients.”
Novel method for discovering pancreatic cancer biomarkers
Credit: The lab of Ken Zaret, Perelman School of Medicine, University of Pennsylvania
The biomarker panel, enabled by discovery work of first author Jungsun Kim, PhD, a postdoctoral fellow in Zaret’s lab, builds on a first-of-its-kind human-cell model of pancreatic cancer progression the lab described in 2013. They used stem-cell technology to create a cell line from a patient with advanced pancreatic ductal adenocarcinoma. Genetically reprogramming late-stage human cancer cells to a stem-cell state enabled them to force the reprogrammed cells to progress to an early cancerous state, revealing secreted blood biomarkers of early-stage disease along the way.
The best candidate biomarker, plasma thrombospondin-2 (THBS2), was screened against 746 cancer and control plasma samples using an inexpensive, commercially available protein-detection assay. The team found that blood levels of THBS2, combined with levels of a known later-stage biomarker called CA19-9, was reliable at detecting the presence of pancreatic cancer in patients.
The team refined the assay with independent investigations of plasma samples from patients with different stages of cancer, from individuals with benign pancreatic disease, and from healthy controls, all obtained from Petersen, who directs the biospecimen resource program for pancreas research at the Mayo Clinic.
“Positive results for THBS2 or CA19-9 concentrations in the blood consistently and correctly identified all stages of the cancer,” Zaret said. “Notably, THBS2 concentrations combined with CA19-9 identified early stages better than any other known method.” The combination panel also improved the ability to distinguish cases of cancer from pancreatitis. The panel will next be validated in a set of samples from pancreatic cancer patients who provided a research blood sample prior to their diagnosis.
The Latest on: Pancreatic cancer
- Blocking cholesterol storage could stop growth of pancreatic tumorson July 7, 2020 at 7:33 am
Blocking cholesterol storage could stop growth of pancreatic tumorsPR NewswireCOLD SPRING HARBOR, N., July 7, 2020COLD SPRING HARBOR, N.
- Study suggests new potential strategy to fight against pancreatic canceron July 6, 2020 at 10:12 am
A University of Michigan-led study is shedding new light on the way pancreatic cancer cells turn nearby connective tissue cells into co-conspirators in their deadly growth. The findings, which appear ...
- ‘Jeopardy!’: Alex Trebek’s Beautiful Gesture For a Contestant Who Died of Pancreatic Canceron July 5, 2020 at 12:08 pm
Host Alex Trebek Is Releasing a Memoir, Here Are 3 Questions We Want Him to Answer In March 2019, Trebek announced to the quiz show’s fans by way of video the sad news that he had been diagnosed with ...
- Artificial intelligence brings pancreatic cancer screening one step closer to realityon July 2, 2020 at 11:42 am
Artificial intelligence (AI) holds promise for enabling earlier detection of pancreatic cancer, which is crucial to saving lives. The potential of AI is showcased in a study to be presented at the ...
- Can Artificial Intelligence Detect Early-Stage Pancreatic Cancer?on July 2, 2020 at 10:09 am
Could artificial intelligence (AI) be used to identify patients with early-stage pancreatic cancer close to 2 years before the disease becomes apparent, and thus harder to treat?
- Rewiring local immune milieu by boosting dendritic cell for pancreatic cancer treatmenton July 2, 2020 at 6:32 am
(Cancer Cell 37, 289–307.e289, 2020) demonstrated that decreased dendritic cell and elevated Th17 cell could explain the immunosuppressive environment of PDAC when compared with that in lung carcinoma ...
- Corcept Begins Enrollment in Phase III Pancreatic Cancer Studyon July 1, 2020 at 8:35 am
Corcept Therapeutics Incorporated CORT announced that it has enrolled the first patient in a phase III study evaluating relacorilant in combination with Celgene’s [now part of Bristol Myers BMY] ...
- Pancreatic Cancer Action Network Funds $4.75 Million Of Innovative Research Through 2020 Competitive Grants Programon June 30, 2020 at 5:22 am
Pancreatic Cancer Action Network Funds $4.75 Million Of Innovative Research Through 2020 Competitive Grants ProgramPR NewswireMANHATTAN BEACH, Calif.
- WD repeat-containing protein 1 maintains β-Catenin activity to promote pancreatic cancer aggressivenesson June 29, 2020 at 3:16 pm
The molecular signature underlying pancreatic ductal adenocarcinoma (PDAC) progression may include key proteins affecting the malignant phenotypes. Here, we aimed to i ...
- Pancreatic Cancer Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027on June 26, 2020 at 10:53 am
The Global Pancreatic Cancer Market is estimated to value over USD 4.7 billion by 2027 end with a CAGR of over ...
via Google News and Bing News